EPS for Surmodics, Inc. (SRDX) Expected At $-0.01

April 25, 2018 - By Kurt Siggers

Surmodics, Inc. (NASDAQ:SRDX) LogoInvestors sentiment decreased to 0.69 in Q4 2017. Its down 0.25, from 0.94 in 2017Q3. It worsened, as 11 investors sold Surmodics, Inc. shares while 44 reduced holdings. 12 funds opened positions while 26 raised stakes. 11.07 million shares or 0.98% less from 11.18 million shares in 2017Q3 were reported.
State Board Of Administration Of Florida Retirement System has 22,922 shares for 0% of their portfolio. Bancorp Of Ny Mellon Corporation owns 155,922 shares. Acadian Asset Mngmt Limited Company, a Massachusetts-based fund reported 127,544 shares. State Street Corporation, Massachusetts-based fund reported 338,160 shares. Meristem Llp accumulated 8,196 shares or 0.08% of the stock. Renaissance Technology Ltd Liability Corp has 0.03% invested in Surmodics, Inc. (NASDAQ:SRDX) for 1.02M shares. Wells Fargo Com Mn has invested 0% of its portfolio in Surmodics, Inc. (NASDAQ:SRDX). Tudor Et Al reported 0.01% in Surmodics, Inc. (NASDAQ:SRDX). Arizona State Retirement reported 22,035 shares. State Of Alaska Department Of Revenue stated it has 2,627 shares or 0% of all its holdings. Schwab Charles Inv Mngmt accumulated 0% or 62,235 shares. Rhumbline Advisers reported 0% of its portfolio in Surmodics, Inc. (NASDAQ:SRDX). Tiaa Cref Invest Management Limited Liability Corp, a New York-based fund reported 57,934 shares. D E Shaw And Incorporated has 88,541 shares. South Dakota Investment Council invested 0.04% of its portfolio in Surmodics, Inc. (NASDAQ:SRDX).

Since December 11, 2017, it had 0 insider purchases, and 2 insider sales for $63,711 activity.

Analysts expect Surmodics, Inc. (NASDAQ:SRDX) to report $-0.01 EPS on April, 26.They anticipate $0.06 EPS change or 120.00 % from last quarter’s $0.05 EPS. After having $0.10 EPS previously, Surmodics, Inc.’s analysts see -110.00 % EPS growth. The stock increased 0.67% or $0.25 during the last trading session, reaching $37.45. About 37,557 shares traded. Surmodics, Inc. (NASDAQ:SRDX) has risen 61.37% since April 26, 2017 and is uptrending. It has outperformed by 49.82% the S&P500.

Surmodics, Inc. (NASDAQ:SRDX) Ratings Coverage

Among 2 analysts covering Surmodics (NASDAQ:SRDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Surmodics had 2 analyst reports since February 28, 2018 according to SRatingsIntel. Barrington Research upgraded the shares of SRDX in report on Wednesday, February 28 to “Outperform” rating.

Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland. The company has market cap of $494.21 million. It operates through two divisions, Medical Device and In Vitro Diagnostics. It has a 18725 P/E ratio. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.

Surmodics, Inc. (NASDAQ:SRDX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: